Who Paid My Doc
Carlos Pantojas
Rheumatology San Juan, PR Medical Doctor
NPI 1144299074 CMS profile 766091
1801 Ave Ponce De Leon, Ste 306, San Juan, PR 00909
General payments
$144
Research payments
$48,920
Ownership & investment interest
$0
Research they led as principal investigator
$3,192,460
Through program year 2025, Carlos Pantojas of San Juan, PR is reported in the CMS Open Payments database as having received $144 across 9 general payments and $48,920 in research payments paid to them. Separately, studies naming them as principal investigator received $3,192,460 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $15 | 1 | |
| 2023 | General | $13 | 1 | |
| 2022 | Research | $19,031 | 16 | |
| 2021 | Research | $17,830 | 10 | |
| 2020 | General | $40 | 1 | |
| 2020 | Research | $10,425 | 9 | |
| 2019 | General | $76 | 6 | |
| 2019 | Research | $1,633 | 4 |
Beside peers
- Carlos Pantojas
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Carlos Pantojas were reported at $15. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Carlos Pantojas | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $76 | $744 | $153–$2,687 | $163 |
| 2020 | $40 | $462 | $98–$2,027 | $114 |
| 2021 | $0 | $531 | $101–$2,153 | $132 |
| 2022 | $0 | $627 | $125–$2,303 | $149 |
| 2023 | $13 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $15 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 48 drugsPart D claims
8,159
Drug cost
$2,584,310
Branded share of claims
13.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 94 | $701,098 | |
| Rinvoq Upadacitinib | Brand | 101 | $651,637 | |
| Humira(Cf) Pen Adalimumab | Brand | 63 | $433,256 | |
| Prolia Denosumab | Brand | 154 | $272,646 | |
| Enbrel Etanercept | Brand | 12 | $87,106 | |
| Humira(Cf) Adalimumab | Brand | 12 | $83,056 | |
| Actemra Tocilizumab | Brand | 20 | $67,889 | |
| Gabapentin | Generic | 1,403 | $34,264 | |
| Pregabalin | Generic | 817 | $33,934 | |
| Evenity (2 Syringes) Romosozumab-Aqqg | Brand | 12 | $29,647 |
The 10 drugs with the highest cost, of 48 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$7,553
Medicare patients
43
Services billed
229
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 65% | |
| Osteoporosis | 40% | |
| Chronic kidney disease | 30% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 25 | 101 | $75 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
48 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in Puerto Rico
Related records
Rheumatology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.